Canalia Combination Tablets, a type 2 diabetes mellitus treatment agent is approved in Japan for Daiichi Sankyo and Mitsubishi Tanabe.
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd announced that on 3 July 2017 Mitsubishi Tanabe received approval in Japan for Canalia Combination Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor Tenelia Tablets (generic name: teneligliptin) and SGLT2 inhibitor Canaglu Tablets (generic name: canagliflozin), from the Japanese Ministry of Health, Labour and Welfare. The approval is for an indication of type 2 diabetes mellitus.
Comment: Currently, marketing of Tenilia Tablets is conducted by Daiichi Sankyo, whereas marketing of Canaglu Tablets is carried out by Mitsubishi Tanabe Pharma. Marketing of Canilia Combination Tablets will be conducted by both companies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.